Tolvaptan for the treatment of heart failure: a review of the literature

Bibliography

• Lloyd-Jones D, Adams RJ, Brown TM, Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 2010;121:e46-215
   PubMed Web of Science ®Google Scholar
• Pang PS, Komajda M, Gheorghiade M. The current and future management of acute heart failure syndromes. Eur Heart J 2010;31:784-93
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Abraham WT, Albert NM, Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217-26
   PubMed Web of Science ®Google Scholar
• Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372-90
   PubMed Web of Science ®Google Scholar
• Lee CR, Watkins ML, Patterson JH, Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003;146:9-18
   PubMed Web of Science ®Google Scholar
• Jard S. Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int Suppl 1988;26:S38-42
   PubMedGoogle Scholar
• Xu YJ, Gopalakrishnan V. Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ Res 1991;69:239-45
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Haneda T, Osaki J, Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 2000;391:39-48
   PubMed Web of Science ®Google Scholar
• Penit J, Faure M, Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol 1983;244:E72-82
   PubMed Web of Science ®Google Scholar
• Nielsen S, Chou CL, Marples D, Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 1995;92:1013-17
   PubMed Web of Science ®Google Scholar
• Kalra PR, Anker SD, Coats AJ. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res 2001;51:495-509
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Francis GS, Cowley AW Jr, Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1:1385-90
   PubMed Web of Science ®Google Scholar
• Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J 1968;32:745-59
   PubMedGoogle Scholar
• Szatalowicz VL, Arnold PE, Chaimovitz C, Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-6
   PubMed Web of Science ®Google Scholar
• Preibisz JJ, Sealey JE, Laragh JH, Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983;5:I129-138
   PubMed Web of Science ®Google Scholar
• Riegger GA, Liebau G, Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med 1982;72:49-52
   PubMed Web of Science ®Google Scholar
• Francis GS, Benedict C, Johnstone DE, Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9
   PubMed Web of Science ®Google Scholar
• Isnard R, Pousset F, Trochu J, Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000;86:417-21
   PubMed Web of Science ®Google Scholar
• Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med 2003;114:625-30
   PubMedGoogle Scholar
• Adamson PB, Magalski A, Braunschweig F, Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003;41:565-71
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006;119:S3-10
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, De Luca L, Fonarow GC, Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005;96:11G-7G
   PubMed Web of Science ®Google Scholar
• Kono T, Sabbah HN, Rosman H, Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 1992;20:1594-8
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Rosman H, Kono T, On the mechanism of functional mitral regurgitation. Am J Cardiol 1993;72:1074-6
   PubMedGoogle Scholar
• Grossman E, Oren S, Messerli FH. Left ventricular filling and stress response pattern in essential hypertension. Am J Med 1991;91:502-6
   PubMed Web of Science ®Google Scholar
• Grossman W. Diastolic dysfunction and congestive heart failure. Circulation 1990;81:III1-7
   PubMedGoogle Scholar
• Hasselblad V, Gattis Stough W, Shah MR, Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-9
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Rossi JS, Cotts W, Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007;167:1998-2005
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Abraham WT, Albert NM, Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980-8
   PubMed Web of Science ®Google Scholar
• Rossi J, Bayram M, Udelson JE, Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007;9:82-6
   PubMedGoogle Scholar
• Klein L, O'Connor CM, Leimberger JD, Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454-60
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Nakamura S, Itoh S, OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287:860-7
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005;96:68G-73G
   Web of Science ®Google Scholar
• Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 2007;47:1498-507
   PubMed Web of Science ®Google Scholar
• Shoaf SE, Elizari MV, Wang Z, Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J Cardiovasc Pharmacol Ther 2005;10:165-71
   PubMed Web of Science ®Google Scholar
• Hirano T, Yamamura Y, Nakamura S, Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000;292:288-94
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Yamamura Y, Onogawa T, Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 2005;146:3037-43
   PubMed Web of Science ®Google Scholar
• Veeraveedu PT, Watanabe K, Ma M, Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure. Biochem Pharmacol 2007;74:1466-75
   PubMedGoogle Scholar
• Veeraveedu PT, Watanabe K, Ma M, Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol 2008;75:1322-30
   PubMedGoogle Scholar
• Miyazaki T, Fujiki H, Yamamura Y, Tolvaptan, an orally active vasopressin V(2)-receptor antagonist – pharmacology and clinical trials. Cardiovasc Drug Rev 2007;25:1-13
   PubMedGoogle Scholar
• Udelson JEOC, O'Brien T, Sequeira R, Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination [abstract]. J Am Coll Cardiol 2002;39:810
   Google Scholar
• Costello-Boerrigter LC, Smith WB, Boerrigter G, Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006;290:F273-278
   PubMed Web of Science ®Google Scholar
• Udelson JE, Orlandi C, Ouyang J, Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:1540-5
   PubMed Web of Science ®Google Scholar
• Paterna S, Di Pasquale P, Parrinello G, Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol 2005;45:1997-2003
   PubMed Web of Science ®Google Scholar
• Udelson JE, McGrew FA, Flores E, Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007;49:2151-9
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gottlieb SS, Udelson JE, Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006;97:1064-7
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M, Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J, Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-6
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O'Connor CM, Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Orlandi C, Burnett JC, Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 2005;11:260-9
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Zannad F, Sopko G, Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-68
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC Jr, Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr, Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007;297:1319-31
   PubMed Web of Science ®Google Scholar
• Berl T, Quittnat-Pelletier F, Verbalis JG, Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-12
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Pang PS, Tavares M, The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010;31:832-41
   PubMedGoogle Scholar
• Yancy CW. Climbing the mountain of acute decompensated heart failure: the EVEREST trials. JAMA 2007;297:1374-6
   PubMed Web of Science ®Google Scholar
• Pang PS, Konstam MA, Krasa HB, Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009;30:2233-40
   PubMed Web of Science ®Google Scholar
• Konstam MA, Rousseau MF, Kronenberg MW, Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-8
   PubMed Web of Science ®Google Scholar
• Greenberg B, Quinones MA, Koilpillai C, Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995;91:2573-81
   PubMed Web of Science ®Google Scholar
• Doughty RN, Whalley GA, Gamble G, Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-6
   PubMed Web of Science ®Google Scholar
• Packer M, Califf RM, Konstam MA, Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Konstam MA, Benedict CR, Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488-93
   PubMed Web of Science ®Google Scholar
• Tahara A, Tomura Y, Wada K, Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998;38:198-205
   PubMed Web of Science ®Google Scholar
• Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem 1999;195:93-8
   PubMed Web of Science ®Google Scholar
• Walker BR, Childs ME, Adams EM. Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. Am J Physiol 1988;255:H261-265
   Web of Science ®Google Scholar
• Goldsmith SR, Francis GS, Cowley AW Jr, Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986;8:779-83
   PubMed Web of Science ®Google Scholar
• Creager MA, Faxon DP, Cutler SS, Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986;7:758-65
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785-91
   PubMed Web of Science ®Google Scholar
• Naitoh M, Suzuki H, Murakami M, Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994;267:H2245-2254
   PubMed Web of Science ®Google Scholar
• Wang YX, Franco R, Gavras I, Gavras H. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. J Lab Clin Med 1991;117:313-18
   PubMedGoogle Scholar
• Nishikimi T, Kawano Y, Saito Y, Matsuoka H. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 1996;27:275-82
   PubMedGoogle Scholar
• Yatsu T, Tomura Y, Tahara A, Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999;376:239-46
   PubMed Web of Science ®Google Scholar
• Mondritzki T, Kolkhof P, Sabbah HN, Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model. Am J Ther 2010
   Google Scholar
• Goldsmith SR, Elkayam U, Haught WH, Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008;14:641-7
   PubMed Web of Science ®Google Scholar